This first self-amplifying mRNA vaccine in Vietnam has been developed by the US-based Arcturus Therapeutics, Inc., who is partnering with Vingroup’s VinBioCare in the clinical trials and manufacturing at the Hoa Lac Hi-tech Park in Hanoi.
mRNA technology helps produce a lower-dose vaccine that can induce a strong immune response to COVID-19 variants such as Alpha, Beta, Delta, and Gamma.
The mRNA vaccine underwent first and second-phase trials in the US and Singapore, where it showed its efficiency.
🔯 In Vietnam, however, it will be tested in human clinical trials in three phases to ensure it is safe for use./.
VNA